OBJECTIVE: To determine whether the combination of triiodothyronine (T3) plus sertraline at treatment initiation confers greater antidepressant efficacy than sertraline plus placebo in patients with major depressive disorder. METHOD: Eight-week, double blind, randomized placebo controlled clinical trial of 153 adult outpatients between 18 and 60 years of age, with DSM-IV defined major depressive disorder. Patients were treated with sertraline flexibly adjusted for tolerability and in a double blind fashion with placebo or T3 (25 μg/day in week 1 and increasing to 50 μg/day in week 2). Response was defined categorically as 50% reduction and total score less than 15 in 21-item Hamilton Rating Scale for Depression (HRSD-21) at week 8 and remission as HRSD-21 less than 8. RESULTS: There was no difference between treatment groups at final assessment; 65% of placebo and 61.8% of T3 treated subjects achieved response and 50.6% of placebo and 40.8% of T3 treated patients achieved remission. The mean daily dose at final assessment of sertraline and T3, respectively was 144.7 mg (± 48.7 mg) and 48.2 μg (± 7 μg). Median time to response did not differ between treatment groups. Baseline thyroid function tests did not predict response to sertraline treatment or T3 augmentation. CONCLUSIONS: These results do not support the routine use of T3 to enhance or accelerate onset of antidepressant response in patients with major depressive disorder.
RCT Entities:
OBJECTIVE: To determine whether the combination of triiodothyronine (T3) plus sertraline at treatment initiation confers greater antidepressant efficacy than sertraline plus placebo in patients with major depressive disorder. METHOD: Eight-week, double blind, randomized placebo controlled clinical trial of 153 adult outpatients between 18 and 60 years of age, with DSM-IV defined major depressive disorder. Patients were treated with sertraline flexibly adjusted for tolerability and in a double blind fashion with placebo or T3 (25 μg/day in week 1 and increasing to 50 μg/day in week 2). Response was defined categorically as 50% reduction and total score less than 15 in 21-item Hamilton Rating Scale for Depression (HRSD-21) at week 8 and remission as HRSD-21 less than 8. RESULTS: There was no difference between treatment groups at final assessment; 65% of placebo and 61.8% of T3 treated subjects achieved response and 50.6% of placebo and 40.8% of T3 treated patients achieved remission. The mean daily dose at final assessment of sertraline and T3, respectively was 144.7 mg (± 48.7 mg) and 48.2 μg (± 7 μg). Median time to response did not differ between treatment groups. Baseline thyroid function tests did not predict response to sertraline treatment or T3 augmentation. CONCLUSIONS: These results do not support the routine use of T3 to enhance or accelerate onset of antidepressant response in patients with major depressive disorder.
Authors: L L Altshuler; M Bauer; M A Frye; M J Gitlin; J Mintz; M P Szuba; K L Leight; P C Whybrow Journal: Am J Psychiatry Date: 2001-10 Impact factor: 18.112
Authors: A John Rush; Madhukar H Trivedi; Jonathan W Stewart; Andrew A Nierenberg; Maurizio Fava; Benji T Kurian; Diane Warden; David W Morris; James F Luther; Mustafa M Husain; Ian A Cook; Richard C Shelton; Ira M Lesser; Susan G Kornstein; Stephen R Wisniewski Journal: Am J Psychiatry Date: 2011-05-02 Impact factor: 18.112
Authors: Bente C Appelhof; Jantien P Brouwer; Richard van Dyck; Eric Fliers; Witte J G Hoogendijk; Jochanan Huyser; Aart H Schene; Jan G P Tijssen; Wilmar M Wiersinga Journal: J Clin Endocrinol Metab Date: 2004-12 Impact factor: 5.958
Authors: Pierre Blier; Herbert E Ward; Philippe Tremblay; Louise Laberge; Chantal Hébert; Richard Bergeron Journal: Am J Psychiatry Date: 2009-12-15 Impact factor: 18.112
Authors: Gabor I Keitner; Steven J Garlow; Christine E Ryan; Philip T Ninan; David A Solomon; Charles B Nemeroff; Martin B Keller Journal: J Psychiatr Res Date: 2008-06-30 Impact factor: 4.791
Authors: Florian Seemüller; Michael Riedel; Michael Obermeier; Michael Bauer; Mazda Adli; Klaus Kronmüller; Florian Holsboer; Peter Brieger; Gerd Laux; Wolfram Bender; Isabella Heuser; Joachim Zeiler; Wolfgang Gaebel; Eva Dichgans; Roland Bottländer; Richard Musil; Hans-Jürgen Möller Journal: Eur Neuropsychopharmacol Date: 2010-01-22 Impact factor: 4.600
Authors: Jonathan W Stewart; Patrick J McGrath; Rodeborah A Deliyannides; Frederic M Quitkin Journal: J Psychiatr Pract Date: 2009-09 Impact factor: 1.325
Authors: Aleksander Kuś; Alisa D Kjaergaard; Eirini Marouli; Fabiola Del Greco M; Rosalie B T M Sterenborg; Layal Chaker; Robin P Peeters; Tomasz Bednarczuk; Bjørn O Åsvold; Stephen Burgess; Panos Deloukas; Alexander Teumer; Christina Ellervik; Marco Medici Journal: Thyroid Date: 2021-05-26 Impact factor: 6.506